Urinary levels of urokinase‐type plasminogen activator and its receptor in the detection of bladder carcinoma
BACKGROUND The authors found previously that plasma levels of urokinase‐type plasminogen activator (uPA) and its receptor (uPAR) were elevated in patients with bladder carcinoma and were associated with features of biologically aggressive disease. In the current study, they tested the hypothesis tha...
Gespeichert in:
| Veröffentlicht in: | Cancer 2002-12, Vol.95 (12), p.2494-2499 |
|---|---|
| Hauptverfasser: | , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 2499 |
|---|---|
| container_issue | 12 |
| container_start_page | 2494 |
| container_title | Cancer |
| container_volume | 95 |
| creator | Casella, Roberto Shariat, Shahrokh F. Monoski, Mara A. Lerner, Seth P. |
| description | BACKGROUND
The authors found previously that plasma levels of urokinase‐type plasminogen activator (uPA) and its receptor (uPAR) were elevated in patients with bladder carcinoma and were associated with features of biologically aggressive disease. In the current study, they tested the hypothesis that elevated urinary levels of uPA and uPAR would predict the presence of bladder malignancy by comparing the performance of uPA and uPAR with the performance of bladder wash‐out cytology in the noninvasive diagnosis of bladder tumors.
METHODS
An enzyme‐linked immunosorbent assay was used to compare levels of uPA and uPAR in urine that was collected before cystoscopy from 122 patients with bladder carcinoma and from 107 participants in a control group. Seventy‐two patients had clinical Tis or Ta transitional cell carcinoma, and 50 patients had invasive disease (≥ T1); 85 patients had clinical Grade 1–2 tumors, and 37 patients had Grade 3 tumors. For cytology, only high grade was considered positive.
RESULTS
Urinary levels of uPA and uPAR were higher in patients with bladder carcinoma compared with levels in the control group (P < 0.001 and P = 0.016, respectively). However, only uPA levels were elevated in patients with abnormal urinary cytology (P = 0.006). After controlling for cytology (odds ratio [OR], 10.182; 95% confidence interval [95%CI], 4.451–23.291; P < 0.001), uPAR (P for trend = 0.168), and age (P = 0.091), those in the highest quartile for uPA had an increased risk of bladder carcinoma compared with those in the lowest quartile (OR, 3.022; 95%CI, 1.295–7.054; P for trend = 0.031).
CONCLUSIONS
The current findings suggest that urinary levels of uPA, but not uPAR, are related to the risk of bladder carcinoma. The study confirmed the central role of urinary cytology in the noninvasive diagnosis of bladder carcinoma. Cancer 2002;95:2494–9. © 2002 American Cancer Society.
DOI 10.1002/cncr.10989
In testing the hypothesis that elevated urinary levels of urokinase‐type plasminogen activator (uPA) and its receptor (uPAR) may predict the presence of bladder malignancy, the authors found that urinary levels of uPA, but not uPAR, add independent information to bladder cytology and are related to the risk of bladder carcinoma. |
| doi_str_mv | 10.1002/cncr.10989 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_72732385</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>72732385</sourcerecordid><originalsourceid>FETCH-LOGICAL-c3919-76d4b06e217f6d7993c2609e945db163159d0dbffa3f4a1525e6b02f130bfb5a3</originalsourceid><addsrcrecordid>eNp9kN1KHDEYhkNRdP056QWUnNiDwtj8zGQ2h7LYWhAFqeDZkEm-aNpMMk1mV_asl9Br9ErMdhc88-j74eF94UHoIyXnlBD2VQedyibn8gOaldlWhNZsD80IIfOqqfnDITrK-Vc5W9bwA3RIWS1aItgMxfvkgkpr7GEFPuNo8TLF3-WX4eXvv2k9Ah69yoML8RECVnpyKzXFhFUw2E0ZJ9Awbh4u4OkJsIEJChTDJqv3yhhIWKukS8KgTtC-VT7D6W4eo_tvlz8XV9X17fcfi4vrSnNJZdUKU_dEAKOtFaaVkmsmiARZN6angtNGGmJ6axW3taINa0D0hFnKSW_7RvFj9HmbO6b4Zwl56gaXNXivAsRl7lrWcsbnTQG_bEGdYs4JbDcmNxQjHSXdRm-30dv911vgT7vUZT-AeUN3PgtwtgNU1srbpIJ2-Y2r69IrSOHolnt2HtbvVHaLm8XdtvwV0mCU9g</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>72732385</pqid></control><display><type>article</type><title>Urinary levels of urokinase‐type plasminogen activator and its receptor in the detection of bladder carcinoma</title><source>Wiley Free Content</source><source>MEDLINE</source><source>Wiley Online Library Journals Frontfile Complete</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>Alma/SFX Local Collection</source><creator>Casella, Roberto ; Shariat, Shahrokh F. ; Monoski, Mara A. ; Lerner, Seth P.</creator><creatorcontrib>Casella, Roberto ; Shariat, Shahrokh F. ; Monoski, Mara A. ; Lerner, Seth P.</creatorcontrib><description>BACKGROUND
The authors found previously that plasma levels of urokinase‐type plasminogen activator (uPA) and its receptor (uPAR) were elevated in patients with bladder carcinoma and were associated with features of biologically aggressive disease. In the current study, they tested the hypothesis that elevated urinary levels of uPA and uPAR would predict the presence of bladder malignancy by comparing the performance of uPA and uPAR with the performance of bladder wash‐out cytology in the noninvasive diagnosis of bladder tumors.
METHODS
An enzyme‐linked immunosorbent assay was used to compare levels of uPA and uPAR in urine that was collected before cystoscopy from 122 patients with bladder carcinoma and from 107 participants in a control group. Seventy‐two patients had clinical Tis or Ta transitional cell carcinoma, and 50 patients had invasive disease (≥ T1); 85 patients had clinical Grade 1–2 tumors, and 37 patients had Grade 3 tumors. For cytology, only high grade was considered positive.
RESULTS
Urinary levels of uPA and uPAR were higher in patients with bladder carcinoma compared with levels in the control group (P < 0.001 and P = 0.016, respectively). However, only uPA levels were elevated in patients with abnormal urinary cytology (P = 0.006). After controlling for cytology (odds ratio [OR], 10.182; 95% confidence interval [95%CI], 4.451–23.291; P < 0.001), uPAR (P for trend = 0.168), and age (P = 0.091), those in the highest quartile for uPA had an increased risk of bladder carcinoma compared with those in the lowest quartile (OR, 3.022; 95%CI, 1.295–7.054; P for trend = 0.031).
CONCLUSIONS
The current findings suggest that urinary levels of uPA, but not uPAR, are related to the risk of bladder carcinoma. The study confirmed the central role of urinary cytology in the noninvasive diagnosis of bladder carcinoma. Cancer 2002;95:2494–9. © 2002 American Cancer Society.
DOI 10.1002/cncr.10989
In testing the hypothesis that elevated urinary levels of urokinase‐type plasminogen activator (uPA) and its receptor (uPAR) may predict the presence of bladder malignancy, the authors found that urinary levels of uPA, but not uPAR, add independent information to bladder cytology and are related to the risk of bladder carcinoma.</description><identifier>ISSN: 0008-543X</identifier><identifier>EISSN: 1097-0142</identifier><identifier>DOI: 10.1002/cncr.10989</identifier><identifier>PMID: 12467062</identifier><identifier>CODEN: CANCAR</identifier><language>eng</language><publisher>New York: Wiley Subscription Services, Inc., A Wiley Company</publisher><subject>Adult ; Aged ; Biological and medical sciences ; bladder carcinoma ; Carcinoma, Transitional Cell - pathology ; Carcinoma, Transitional Cell - urine ; Case-Control Studies ; Female ; Genital system. Mammary gland ; Humans ; Investigative techniques, diagnostic techniques (general aspects) ; Male ; Medical sciences ; Middle Aged ; Neoplasm Invasiveness ; Neoplasm Staging ; Pathology. Cytology. Biochemistry. Spectrometry. Miscellaneous investigative techniques ; Prospective Studies ; Receptors, Cell Surface - metabolism ; Receptors, Urokinase Plasminogen Activator ; Risk Factors ; transitional cell carcinoma ; Urinary Bladder - metabolism ; Urinary Bladder Neoplasms - pathology ; Urinary Bladder Neoplasms - urine ; urine cytology ; Urokinase-Type Plasminogen Activator - urine ; urokinase‐type plasminogen activator ; urokinase‐type plasminogen activator receptor</subject><ispartof>Cancer, 2002-12, Vol.95 (12), p.2494-2499</ispartof><rights>Copyright © 2002 American Cancer Society</rights><rights>2003 INIST-CNRS</rights><rights>Copyright 2002 American Cancer Society.DOI 10.1002/cncr.10989</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c3919-76d4b06e217f6d7993c2609e945db163159d0dbffa3f4a1525e6b02f130bfb5a3</citedby><cites>FETCH-LOGICAL-c3919-76d4b06e217f6d7993c2609e945db163159d0dbffa3f4a1525e6b02f130bfb5a3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1002%2Fcncr.10989$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1002%2Fcncr.10989$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>314,776,780,1411,1427,27901,27902,45550,45551,46384,46808</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=14427360$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/12467062$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Casella, Roberto</creatorcontrib><creatorcontrib>Shariat, Shahrokh F.</creatorcontrib><creatorcontrib>Monoski, Mara A.</creatorcontrib><creatorcontrib>Lerner, Seth P.</creatorcontrib><title>Urinary levels of urokinase‐type plasminogen activator and its receptor in the detection of bladder carcinoma</title><title>Cancer</title><addtitle>Cancer</addtitle><description>BACKGROUND
The authors found previously that plasma levels of urokinase‐type plasminogen activator (uPA) and its receptor (uPAR) were elevated in patients with bladder carcinoma and were associated with features of biologically aggressive disease. In the current study, they tested the hypothesis that elevated urinary levels of uPA and uPAR would predict the presence of bladder malignancy by comparing the performance of uPA and uPAR with the performance of bladder wash‐out cytology in the noninvasive diagnosis of bladder tumors.
METHODS
An enzyme‐linked immunosorbent assay was used to compare levels of uPA and uPAR in urine that was collected before cystoscopy from 122 patients with bladder carcinoma and from 107 participants in a control group. Seventy‐two patients had clinical Tis or Ta transitional cell carcinoma, and 50 patients had invasive disease (≥ T1); 85 patients had clinical Grade 1–2 tumors, and 37 patients had Grade 3 tumors. For cytology, only high grade was considered positive.
RESULTS
Urinary levels of uPA and uPAR were higher in patients with bladder carcinoma compared with levels in the control group (P < 0.001 and P = 0.016, respectively). However, only uPA levels were elevated in patients with abnormal urinary cytology (P = 0.006). After controlling for cytology (odds ratio [OR], 10.182; 95% confidence interval [95%CI], 4.451–23.291; P < 0.001), uPAR (P for trend = 0.168), and age (P = 0.091), those in the highest quartile for uPA had an increased risk of bladder carcinoma compared with those in the lowest quartile (OR, 3.022; 95%CI, 1.295–7.054; P for trend = 0.031).
CONCLUSIONS
The current findings suggest that urinary levels of uPA, but not uPAR, are related to the risk of bladder carcinoma. The study confirmed the central role of urinary cytology in the noninvasive diagnosis of bladder carcinoma. Cancer 2002;95:2494–9. © 2002 American Cancer Society.
DOI 10.1002/cncr.10989
In testing the hypothesis that elevated urinary levels of urokinase‐type plasminogen activator (uPA) and its receptor (uPAR) may predict the presence of bladder malignancy, the authors found that urinary levels of uPA, but not uPAR, add independent information to bladder cytology and are related to the risk of bladder carcinoma.</description><subject>Adult</subject><subject>Aged</subject><subject>Biological and medical sciences</subject><subject>bladder carcinoma</subject><subject>Carcinoma, Transitional Cell - pathology</subject><subject>Carcinoma, Transitional Cell - urine</subject><subject>Case-Control Studies</subject><subject>Female</subject><subject>Genital system. Mammary gland</subject><subject>Humans</subject><subject>Investigative techniques, diagnostic techniques (general aspects)</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Middle Aged</subject><subject>Neoplasm Invasiveness</subject><subject>Neoplasm Staging</subject><subject>Pathology. Cytology. Biochemistry. Spectrometry. Miscellaneous investigative techniques</subject><subject>Prospective Studies</subject><subject>Receptors, Cell Surface - metabolism</subject><subject>Receptors, Urokinase Plasminogen Activator</subject><subject>Risk Factors</subject><subject>transitional cell carcinoma</subject><subject>Urinary Bladder - metabolism</subject><subject>Urinary Bladder Neoplasms - pathology</subject><subject>Urinary Bladder Neoplasms - urine</subject><subject>urine cytology</subject><subject>Urokinase-Type Plasminogen Activator - urine</subject><subject>urokinase‐type plasminogen activator</subject><subject>urokinase‐type plasminogen activator receptor</subject><issn>0008-543X</issn><issn>1097-0142</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2002</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9kN1KHDEYhkNRdP056QWUnNiDwtj8zGQ2h7LYWhAFqeDZkEm-aNpMMk1mV_asl9Br9ErMdhc88-j74eF94UHoIyXnlBD2VQedyibn8gOaldlWhNZsD80IIfOqqfnDITrK-Vc5W9bwA3RIWS1aItgMxfvkgkpr7GEFPuNo8TLF3-WX4eXvv2k9Ah69yoML8RECVnpyKzXFhFUw2E0ZJ9Awbh4u4OkJsIEJChTDJqv3yhhIWKukS8KgTtC-VT7D6W4eo_tvlz8XV9X17fcfi4vrSnNJZdUKU_dEAKOtFaaVkmsmiARZN6angtNGGmJ6axW3taINa0D0hFnKSW_7RvFj9HmbO6b4Zwl56gaXNXivAsRl7lrWcsbnTQG_bEGdYs4JbDcmNxQjHSXdRm-30dv911vgT7vUZT-AeUN3PgtwtgNU1srbpIJ2-Y2r69IrSOHolnt2HtbvVHaLm8XdtvwV0mCU9g</recordid><startdate>20021215</startdate><enddate>20021215</enddate><creator>Casella, Roberto</creator><creator>Shariat, Shahrokh F.</creator><creator>Monoski, Mara A.</creator><creator>Lerner, Seth P.</creator><general>Wiley Subscription Services, Inc., A Wiley Company</general><general>Wiley-Liss</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20021215</creationdate><title>Urinary levels of urokinase‐type plasminogen activator and its receptor in the detection of bladder carcinoma</title><author>Casella, Roberto ; Shariat, Shahrokh F. ; Monoski, Mara A. ; Lerner, Seth P.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c3919-76d4b06e217f6d7993c2609e945db163159d0dbffa3f4a1525e6b02f130bfb5a3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2002</creationdate><topic>Adult</topic><topic>Aged</topic><topic>Biological and medical sciences</topic><topic>bladder carcinoma</topic><topic>Carcinoma, Transitional Cell - pathology</topic><topic>Carcinoma, Transitional Cell - urine</topic><topic>Case-Control Studies</topic><topic>Female</topic><topic>Genital system. Mammary gland</topic><topic>Humans</topic><topic>Investigative techniques, diagnostic techniques (general aspects)</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Middle Aged</topic><topic>Neoplasm Invasiveness</topic><topic>Neoplasm Staging</topic><topic>Pathology. Cytology. Biochemistry. Spectrometry. Miscellaneous investigative techniques</topic><topic>Prospective Studies</topic><topic>Receptors, Cell Surface - metabolism</topic><topic>Receptors, Urokinase Plasminogen Activator</topic><topic>Risk Factors</topic><topic>transitional cell carcinoma</topic><topic>Urinary Bladder - metabolism</topic><topic>Urinary Bladder Neoplasms - pathology</topic><topic>Urinary Bladder Neoplasms - urine</topic><topic>urine cytology</topic><topic>Urokinase-Type Plasminogen Activator - urine</topic><topic>urokinase‐type plasminogen activator</topic><topic>urokinase‐type plasminogen activator receptor</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Casella, Roberto</creatorcontrib><creatorcontrib>Shariat, Shahrokh F.</creatorcontrib><creatorcontrib>Monoski, Mara A.</creatorcontrib><creatorcontrib>Lerner, Seth P.</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Cancer</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Casella, Roberto</au><au>Shariat, Shahrokh F.</au><au>Monoski, Mara A.</au><au>Lerner, Seth P.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Urinary levels of urokinase‐type plasminogen activator and its receptor in the detection of bladder carcinoma</atitle><jtitle>Cancer</jtitle><addtitle>Cancer</addtitle><date>2002-12-15</date><risdate>2002</risdate><volume>95</volume><issue>12</issue><spage>2494</spage><epage>2499</epage><pages>2494-2499</pages><issn>0008-543X</issn><eissn>1097-0142</eissn><coden>CANCAR</coden><abstract>BACKGROUND
The authors found previously that plasma levels of urokinase‐type plasminogen activator (uPA) and its receptor (uPAR) were elevated in patients with bladder carcinoma and were associated with features of biologically aggressive disease. In the current study, they tested the hypothesis that elevated urinary levels of uPA and uPAR would predict the presence of bladder malignancy by comparing the performance of uPA and uPAR with the performance of bladder wash‐out cytology in the noninvasive diagnosis of bladder tumors.
METHODS
An enzyme‐linked immunosorbent assay was used to compare levels of uPA and uPAR in urine that was collected before cystoscopy from 122 patients with bladder carcinoma and from 107 participants in a control group. Seventy‐two patients had clinical Tis or Ta transitional cell carcinoma, and 50 patients had invasive disease (≥ T1); 85 patients had clinical Grade 1–2 tumors, and 37 patients had Grade 3 tumors. For cytology, only high grade was considered positive.
RESULTS
Urinary levels of uPA and uPAR were higher in patients with bladder carcinoma compared with levels in the control group (P < 0.001 and P = 0.016, respectively). However, only uPA levels were elevated in patients with abnormal urinary cytology (P = 0.006). After controlling for cytology (odds ratio [OR], 10.182; 95% confidence interval [95%CI], 4.451–23.291; P < 0.001), uPAR (P for trend = 0.168), and age (P = 0.091), those in the highest quartile for uPA had an increased risk of bladder carcinoma compared with those in the lowest quartile (OR, 3.022; 95%CI, 1.295–7.054; P for trend = 0.031).
CONCLUSIONS
The current findings suggest that urinary levels of uPA, but not uPAR, are related to the risk of bladder carcinoma. The study confirmed the central role of urinary cytology in the noninvasive diagnosis of bladder carcinoma. Cancer 2002;95:2494–9. © 2002 American Cancer Society.
DOI 10.1002/cncr.10989
In testing the hypothesis that elevated urinary levels of urokinase‐type plasminogen activator (uPA) and its receptor (uPAR) may predict the presence of bladder malignancy, the authors found that urinary levels of uPA, but not uPAR, add independent information to bladder cytology and are related to the risk of bladder carcinoma.</abstract><cop>New York</cop><pub>Wiley Subscription Services, Inc., A Wiley Company</pub><pmid>12467062</pmid><doi>10.1002/cncr.10989</doi><tpages>6</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0008-543X |
| ispartof | Cancer, 2002-12, Vol.95 (12), p.2494-2499 |
| issn | 0008-543X 1097-0142 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_72732385 |
| source | Wiley Free Content; MEDLINE; Wiley Online Library Journals Frontfile Complete; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; Alma/SFX Local Collection |
| subjects | Adult Aged Biological and medical sciences bladder carcinoma Carcinoma, Transitional Cell - pathology Carcinoma, Transitional Cell - urine Case-Control Studies Female Genital system. Mammary gland Humans Investigative techniques, diagnostic techniques (general aspects) Male Medical sciences Middle Aged Neoplasm Invasiveness Neoplasm Staging Pathology. Cytology. Biochemistry. Spectrometry. Miscellaneous investigative techniques Prospective Studies Receptors, Cell Surface - metabolism Receptors, Urokinase Plasminogen Activator Risk Factors transitional cell carcinoma Urinary Bladder - metabolism Urinary Bladder Neoplasms - pathology Urinary Bladder Neoplasms - urine urine cytology Urokinase-Type Plasminogen Activator - urine urokinase‐type plasminogen activator urokinase‐type plasminogen activator receptor |
| title | Urinary levels of urokinase‐type plasminogen activator and its receptor in the detection of bladder carcinoma |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-09T21%3A31%3A42IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Urinary%20levels%20of%20urokinase%E2%80%90type%20plasminogen%20activator%20and%20its%20receptor%20in%20the%20detection%20of%20bladder%20carcinoma&rft.jtitle=Cancer&rft.au=Casella,%20Roberto&rft.date=2002-12-15&rft.volume=95&rft.issue=12&rft.spage=2494&rft.epage=2499&rft.pages=2494-2499&rft.issn=0008-543X&rft.eissn=1097-0142&rft.coden=CANCAR&rft_id=info:doi/10.1002/cncr.10989&rft_dat=%3Cproquest_cross%3E72732385%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=72732385&rft_id=info:pmid/12467062&rfr_iscdi=true |